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Lysosomal Storage Disorders (LSDs)
 Large group of inherited metabolic disorders (>50)
 The majority are caused by deficiencies in specific
lysosomal enzymes
 Individually rare
 Autosomal recessive (majority)
 Prevalence as a group is estimated in 1:4000 – 1:8000
live births
Progressive lysosomal accumulation of undegraded metabolites results:
- generalised cell and tissue dysfunction
- multi-systemic pathology
early and severe 
phenotype 
 Clinical presentation:
can vary 
late-onset 
mild disease
Reviewed in Filocamo and Morrone, 2011
 Study of 2 different splice donor site mutations
2 patients diagnosed with different LSDs found
Patient Allele 1 Allele 2 Location
Patient 1 (MPS I) c.1650+5G>A c.1205G>A (p.W402X) Intron 11/Exon 9
Patient 2 (ML III α/β) c.3335+6T>G c.2864C>T (p.A955V) Intron 17/Exon 14
Project SPLICETHER from FCT (PTDC /BBB-BMD/6301/2014)
Work in progress : 
 Splicing mutations are frequent in these pathologies (10 to ~16% of the mutations described) 
Good targets for mutation specific 
U1 snRNA therapeutic approaches
5’ donor site mutations
~64% MPS I
~47% ML III α/β
 To correct the pathogenic effect of both splice donor site mutations through
U1 snRNA-mediated therapeutic strategies
Main aim: 
Mucopolysaccharidosis I
(Hurler; Hurler-Scheie; Scheie syndromes)
 Autossomal recessive disorder
 Caused by mutations in IDUA gene (14 exons)
α-L-Iduronidase
Responsible for the degradation of 
Therapy:
 Enzyme replacement therapy – laronidase (Aldurazyme®)
 Hematopoietic stem cell transplantation 
Still with some 
limitations
Development of alternative or adjunct
therapies would be important
dermatan and heparan sulfate
Mucopolysaccharidosis  I
 IDUA gene mutation analysis (RT-PCR)
c.1650+5G>A/p.W402X
Primers for exon 9 and 12:
- Normal length transcript
- One with exon 11 skipping due to 
the donor site mutation
Patient 1: two transcripts
- One with normal length arising from
the nonsense allele
NC WT P1
500 bp
Heteroduplex
200 bp
M
9 10 11 12
Exon

109 12
1. Analysis of IDUA exon 11 splice donor sites (SDS)
Loss of 
 Splicing therapeutic approach for the +5 IDUA gene mutation 
with modified U1 vectors
U1 WTGUCcauucaua3’ 3’ U1 WTGUCcauucaua
Mucopolysaccharidosis  I
base 
pairing (+5)
IDUA exon 11 
WT SDS
CAGgcaagugg…Exon 11
Splice donor site
5’
2. Design and construction of U1 modified vectors (pG3U1)
Increased complementarity to the SDS
U1 IDUA mut 2 (+2G) 3’…GUCcguucaua…
5’…CAGgcaaaugg…Exon 11 mutant SDS
b) 
U1 IDUA mut 3 
(+2G;+5T;+7C;+8C)
3’…GUCcguuuacc…
5’…CAGgcaaaugg…Exon 11 mutant SDSc) a) 
U1 IDUA mut 1 (+5T)
5’…CAGgcaaaugg…
3’…GUCcauuuaua…
Exon 11 mutant SDS
IDUA exon 11 
mutant SDS
CAGgcaaaugg…Exon 11
Splice donor site
5’
X
 Transfection of wild-type and patient 1 fibroblasts with 2.5 µg 
of modified U1 vectors for 24 h
Primers for exon 9 and 12:
 RT-PCR analysis
Wild-type control Patient 1
Mucopolysaccharidosis  I
M WTNC P1
500 bp
300 bp 109 12
9 10 11 12
Exon

Heteroduplex
c.1205G>A
No heterozygous peak 
Not even a partial 
correction observed
→ No correction with 3.5 or 4.5 µg of each 
U1 vector or even in a 48 h treatment 
Mucolipidosis  III alpha/beta
(pseudoHurler polydystrophy)
 Autossomal recessive disorder
 Caused by mutations in GNPTAB gene (21 exons)
α/β-subunit of the N-acetylglucosamine 
(GlcNAc)-1-phosphotransferase
Therapy:
 No causal therapies available for treatment
 Disease management only symptomatic  
Development of therapeutic strategies is essential
Formation of the mannose-6-phosphate 
residues on lysosomal enzymes
 GNPTAB gene mutation analysis (RT-PCR)
c.3335+6T>G/p.A955V
Primers for exon 13 and 18:
Mucolipidosis III alpha/beta
- Normal length transcript
- One with exon 17 skipping due to the donor site mutation
Patient 2: two transcripts
- One with normal length arising from the missense allele
M NC WT P2
500 bp
800 bp Exon
13 14 15 16 17 18
13 14 15 16 18
1. Analysis of GNPTAB exon 17 splice donor sites (SDS)
Loss of 
 Splicing therapeutic approach for the +6 GNPTAB gene mutation 
with modified U1 vectors 
U1 WTGUCcauucaua3’ 3’ U1 WTGUCcauucaua
Mucolipidosis III alpha/beta
base 
pairing (+6)
2. Design and construction of U1 modified vectors (pG3U1)
GNPTAB exon 17 
WT SDS
UAGguaaguag…Exon 17
Splice donor site
5’
a) 
U1 GNPTAB mut 1 (+6C)
5’…UAGguaaggag…
3’…GUCcauuccua…
Exon 17 mutant SDS
b) 
U1 GNPTAB mut 2
(-3A;+6C;+8C)
5’…UAGguaaggag…
3’…AUCcauuccuc…
Exon 17 mutant SDS
GNPTAB exon 17
mutant SDS
UAGguaaggag…Exon 17
Splice donor site
5’
X
Increased complementarity to the SDS
 Transfection of wild-type and patient 2 fibroblasts with 2.5 µg 
of modified U1 vectors for 24 h
Primers for exon 13 and 18:
 RT-PCR analysis
Wild-type 
control Patient 2
Mucolipidosis III alpha/beta
500 bp
M NC WT P2
800 bp
13 14 15 16 18
Exon
13 14 15 16 17 18
c.2864C>T
No heterozygous peak 
Not even a partial 
correction observed
→ No correction with 3.5 or 4.5 µg of each 
U1 vector or even in a 48 h treatment 
Transfection results conclusions
 Absence of correction for both 5’ splice site mutations 
- High level of cell death after transfection
- Presence of different modified U1’s (?)
- Lipo-mediated transfection toxicity (?)
Low transfection eficiency? 
 Co-transfection of minigene constructs with the U1’s (Hep 3B cell line)
 Lentiviral transduction of U1’s in patients fibroblasts
Next steps:
Minigenes expression (Hep 3B)
• MPS I (IDUA minigenes)
Intron 11
Exon 11 Exon 12
Splice Donor Splice AcceptorpSPL3 vector
Intron 10 Intron 12
SA2SD6
EcoRI
EcoRI EcoRI
• ML III α/β (GNPTAB minigenes)
Splice Donor Splice AcceptorpSPL3 vector
SA2SD6
EcoRI
Exon 17
Intron 16 Intron 17
EcoRI EcoRI
• RT-PCR analysis
Exon 11/Intron 11
Wild-type: …CCGGGCAGgcaagtgg…
Mutant: …CCGGGCAGgcaaatgg…
c.1650+5G>A
Exon 17/Intron 17
Wild-type: … AAATATAGgtaagtag…
Mutant: … AAATATAGgtaaggag…
c.3335+6T>G
M NC
Minigene
500 bp
200 bp
V V
Exon 12V V
Exon 17V V

Minigenes:
- WT intron 11
- c.1650+5G>A
- c.3335+6T>G
- WT intron 17

X

Minigenes co-transfection with different U1’s (Hep 3B)
• MPS I – IDUA gene (RT-PCR analysis)
M NC
500 bp
200 bp
c.1650+5G>A minigene
Exon 12V V
V V
Exon 12V VExon 11X
 New constructs!
• ML III α/β – GNPTAB gene (RT-PCR analysis)
M NC
500 bp
200 bp
c.3335+6T>G minigeneWT intron 17 minigene
V V
Exon 17V V
Insertion of exon 17
Short term scientific mission
Learn and perform the lentiviral transduction technique of the different
modified U1’s into patients’ fibroblasts to try the therapeutic rescue of the 5’
splice site mutations, c.1650+5G>A (IDUA gene) and c.3335+6T>G (GNPTAB gene)
Main aim:
 Some different splice donor site mutations have been partially or 
totally rescued through viral transduction of U1 snRNAs (Glaus et al., 
2011; Schmid et al., 2011; Dal Mas et al., 2015)
 Lentiviral transduction of U1 constructs in fibroblasts
 More efficient technique to the acquisition of external vectors  
 Less toxic for cells than lipo-mediated transfection ( ↓ mortality )
Workflow
1. Cloning of the different U1 snRNAs in the lentiviral vector 
U1 WT
U1 IDUA mut 1 
U1 IDUA mut 2 
U1 IDUA mut 3
pG3U1
U1 GNPTAB mut 1 
U1 GNPTAB mut 2 
G
F
P
p.RRLSIN.cPPT.
SFFV/GFP.WPRE
2. HEK293T cells infection for lentivirus production
G
F
P
p.RRLSIN.cPPT.
SFFV/GFP.WPRE
pSPAX2 + +
pMD2.G 
(VSV-G) 
Transfection
HEK293T
Harvest:
- 24 h
- 48 h
Lentiviral vector supernatant
3. Lentivirus transduction in fibroblast cells
 MPS I patient (c.1650+5G>A)
 ML III α/β patient (c.3335+6T>G)
 Wild-type control
 Positive control (BBS-1 gene)  
Schmid et al., 2011
5 ml
Cells harvest 
after 4 days 
 RT-PCR analysis
- Splicing pattern
 qPCR analysis
- Nr of lentivirus copies
Lentiviral transduction results: MPS I
 RT-PCR analysis
M NC
1000 bp
500 bp
Wild-type control Patient 1 (c.1650+5G>A)
9 10 11 12
Exon

109 12
 qPCR analysis
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Nr of lentivirus copies = 2(1+∆Cq)
Albumin (n=2) vs GFP (n=?)
Reference gene vs Target gene:
Lentiviral transduction results: ML III α/β
 RT-PCR analysis
M NC
1000 bp
13 14 15 16 18
Exon
13 14 15 16 17 18
Wild-type control Patient 2 (c.3335+6T>G)
500 bp
 qPCR analysis
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Nr of lentivirus copies = 2(1+∆Cq)
Albumin (n=2) vs GFP (n=?)
Reference gene vs Target gene:
Lentiviral transduction results: BBS (+ control)
c.479G>A 
Last nt exon 5
1 3 6 9
lentiviral 
supernatant (ml)
 ML III α/β parallel experiment
M
500 bp
100 bp
BBS patient
5 ml 
lentiviral 
supernatant
Fully-adapted
 MPS I (c.1650+5G>A)
 ML III α/β (c.3335+6T>G)
- ↑ lentivirus volume
- Optimization !!!
Our cases:
Main STSM achievements
 Cloning of different modified U1’s in a lentiviral vector (p.RRLSIN.cPPT.SFFV/GFP.WPRE) 
 Learning and performing the lentiviral transduction technique in
human fibroblasts
 Obtaining the preliminary results of the lentiviral transduction of
different modified U1’s into MPS I and ML III α/β patients’ fibroblasts to
try the therapeutic rescue of the 5’ ss mutations c.1650+5G>A and
c.3335+6T>G
 Acquisition of the lentiviral transduction technique allowing, in a near
future, its implementation in our laboratory to be applied not only to
the 5’ ss mutations in study as to other donor site mutations reported in
LSDs patient’s
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